The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Oct. 19, 2010
Filed:
Apr. 18, 2006
Masanobu Shinoda, Tsukuba, JP;
Fumiyoshi Matsuura, Tsukuba, JP;
Kaoru Murata, Tsukuba, JP;
Masaharu Gotoda, Tsukuba, JP;
Kenji Hayashi, Tsukuba, JP;
Manabu Sasho, Tokyo, JP;
Naoki Ozeki, Tsukuba, JP;
Susumu Inoue, Hasaki-Machi, JP;
Katsutoshi Nishiura, Hasaki-Machi, JP;
Yoshihiko Hisatake, Hasaki-Machi, JP;
Teiji Takigawa, Hasaki-Machi, JP;
Mamoru Miyazawa, Hasaki-Machi, JP;
Shigeto Negi, Hasaki-Machi, JP;
Keisuke Matsuyama, Kobe, JP;
Masanobu Shinoda, Tsukuba, JP;
Fumiyoshi Matsuura, Tsukuba, JP;
Kaoru Murata, Tsukuba, JP;
Masaharu Gotoda, Tsukuba, JP;
Kenji Hayashi, Tsukuba, JP;
Manabu Sasho, Tokyo, JP;
Naoki Ozeki, Tsukuba, JP;
Susumu Inoue, Hasaki-Machi, JP;
Katsutoshi Nishiura, Hasaki-Machi, JP;
Yoshihiko Hisatake, Hasaki-Machi, JP;
Teiji Takigawa, Hasaki-Machi, JP;
Mamoru Miyazawa, Hasaki-Machi, JP;
Shigeto Negi, Hasaki-Machi, JP;
Keisuke Matsuyama, Kobe, JP;
Eisai R&D Management Co., Ltd., Tokyo, JP;
Abstract
The present invention relates to calcium bis[(2S)-3-[3-[(2S)-3-(4-chloro-2-cyanophenoxy) -2-fluoropropoxy]phenyl]-2-isopropoxypropionate] represented by formula (I), a hydrate thereof, a crystal of the compound of formula (I), and a crystal of the hydrate of the compound of formula (I) which are useful as pharmaceuticals, and to processes for producing the same, and intermediates therefore, and processes for production thereof. There is need for (2S)-3-[3-[(2S)-3-(4 -chloro-2-cyanophenoxy)-2-fluoropropoxy]phenyl]-2-isopropoxypropionic acid, in the form of a drug substance, purified so as to minimize a residual solvent content and having a uniformized specification and a highly favorable workability, and a process for producing the same. Crystalline calcium bis[(2S)-3-[3-[(2S)-3-(4 -chloro-2-cyanophenoxy)-2-fluoropropoxy]phenyl]-2-isopropoxypropionate], a calcium salt of (2S) -3-[3-[(2S)-3-(4-chloro-2-cyanophenoxy)-2-fluoropropoxy]phenyl]-2-isopropoxypropionic acid, solves the above problem.